Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Current Assets (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Current Assets for 8 consecutive years, with $118.7 million as the latest value for Q4 2025.

  • Quarterly Current Assets rose 25.0% to $118.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $118.7 million through Dec 2025, up 25.0% year-over-year, with the annual reading at $118.7 million for FY2025, 25.0% up from the prior year.
  • Current Assets for Q4 2025 was $118.7 million at Precision Biosciences, up from $51.7 million in the prior quarter.
  • The five-year high for Current Assets was $247.7 million in Q2 2022, with the low at $51.7 million in Q3 2025.
  • Average Current Assets over 5 years is $149.5 million, with a median of $146.9 million recorded in 2023.
  • The sharpest move saw Current Assets surged 53.23% in 2021, then tumbled 53.22% in 2025.
  • Over 5 years, Current Assets stood at $161.8 million in 2021, then rose by 23.09% to $199.1 million in 2022, then crashed by 31.51% to $136.4 million in 2023, then plummeted by 30.34% to $95.0 million in 2024, then rose by 25.0% to $118.7 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $118.7 million, $51.7 million, and $70.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.